The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The
amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken
with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be
measured. Information about any side effects that may occur will also be collected.
Participants will be on study for 21 days with a follow-up at least 7 days afterwards.
Screening will be undertaken within 45 days prior to enrollment.